
TWiV 1018: Clinical update with Dr. Daniel Griffin
About this episode
In his weekly clinical update, Dr. Griffin discusses the CDC vaccine advisory group recommending the newly approved RSV vaccines, association of culturable-virus detection and household transmission of SARS-CoV-2, prevention of COVID-19 following a single intramuscular administration of Adintrevimab, real-world effectiveness of Nirmatrelvir/Ritonavir on COVID-19, and COVID-19 convalescent plasma outpatient therapy to prevent outpatient hospitalization.
Subscribe (free): Apple Podcasts, Google Podcasts, RSS, email
Become a patron of TWiV!
Links for this episode
- CDC vaccine advisory group recommends RSV vaccines
- Association of culturable-virus detection and household transmission of SARS-CoV-2 (JID)
- Prevention of COVID-19 following intramuscular administration of Adintrevimab (OFID)
- Real-world effectiveness of Nirmatrelvir/Ritonavir on COVID-19 (CID)
- COVID-19 convalescent plasma outpatient therapy to prevent hospitalization (CID)
- Contribute to our FIMRC fundraiser at PWB
- Letters read on TWiV 1018
- Dr. Griffin's COVID treatment summary (pdf)
- Timestamps by Jolene. Thanks!
Intro music is by Ronald Jenkees
Send your questions for Dr. Griffin to [email protected]
Get every episode summarized
Each time This Week in Virology publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from This Week in Virology

TWiV 1309: Maybe they're all cancer vaccines
This Week in Virology

TWiV 1308: Clinical update with Dr. Daniel Griffin
This Week in Virology

TWiV 1307: My heart breaks for flu
This Week in Virology

TWiV 1306: Clinical update with Dr. Daniel Griffin
This Week in Virology